ノヴォ・ノルディスクの新型糖尿病と重症薬アミクリチンは14. 5%減量し,中期試験で糖糖の制御を改善した. Novo Nordisk's new diabetes and weight-loss drug, amycretin, showed up to 14.5% weight loss and improved blood sugar control in mid-stage trials.

Novo Nordiskは,臨床臨床試験で陽性の結果を発表し,実験的な糖尿病と重量服薬アミクレチンが14.5%も減少し,3週間以上で2型糖尿病を患った患者に著しく血糖が制限されていることを示している. Novo Nordisk announced positive mid-stage trial results for its experimental diabetes and weight-loss drug amycretin, showing up to 14.5% weight loss and significant blood sugar control in people with type 2 diabetes over 36 weeks. 1週間に1回の注射と1日1回の口腔注射は,前項より上等に,注射患者の89.1%,口腔患者の77.6%が対象HBA1Cレベルを達成. The once-weekly injection and once-daily oral forms outperformed placebo, with 89.1% of injection patients and 77.6% of oral patients achieving target HbA1c levels. GLP-1とアミリンホルモンを模倣する薬は,一般に安全かつ有効だった. The drug, which mimics GLP-1 and amylin hormones, was generally safe and well-tolerated. 同社は2026年に試験の最終段階を開始する予定で,アミクレチンは現在の糖尿病と減量薬の潜在的な後継者だと考えている. The company plans to begin late-stage trials in 2026 and sees amycretin as a potential successor to its current diabetes and weight-loss drugs.